DK1542668T3 - Formulering af aripiprazolkompleks og fremgangsmåde - Google Patents
Formulering af aripiprazolkompleks og fremgangsmådeInfo
- Publication number
- DK1542668T3 DK1542668T3 DK03751859T DK03751859T DK1542668T3 DK 1542668 T3 DK1542668 T3 DK 1542668T3 DK 03751859 T DK03751859 T DK 03751859T DK 03751859 T DK03751859 T DK 03751859T DK 1542668 T3 DK1542668 T3 DK 1542668T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulation
- aripiprazole
- complex
- aripiprazole complex
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 229960004372 aripiprazole Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40471302P | 2002-08-20 | 2002-08-20 | |
PCT/US2003/025573 WO2004017897A2 (en) | 2002-08-20 | 2003-08-14 | Aripiprazole complex formulation and method |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1542668T3 true DK1542668T3 (da) | 2009-07-20 |
Family
ID=31946748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03751859T DK1542668T3 (da) | 2002-08-20 | 2003-08-14 | Formulering af aripiprazolkompleks og fremgangsmåde |
Country Status (32)
Country | Link |
---|---|
US (8) | US7115587B2 (da) |
EP (1) | EP1542668B1 (da) |
JP (1) | JP4729306B2 (da) |
KR (1) | KR101043866B1 (da) |
CN (1) | CN100335047C (da) |
AR (2) | AR040887A1 (da) |
AT (1) | ATE428423T1 (da) |
AU (1) | AU2003269965B2 (da) |
BR (1) | BR0313602A (da) |
CA (1) | CA2495864C (da) |
CY (1) | CY1110331T1 (da) |
DE (1) | DE60327225D1 (da) |
DK (1) | DK1542668T3 (da) |
ES (1) | ES2322953T3 (da) |
GE (1) | GEP20063996B (da) |
HR (1) | HRP20050149B1 (da) |
IL (1) | IL166623A (da) |
IS (1) | IS2878B (da) |
MX (1) | MXPA05001865A (da) |
MY (1) | MY140793A (da) |
NO (1) | NO333458B1 (da) |
NZ (1) | NZ537995A (da) |
PE (1) | PE20040895A1 (da) |
PL (1) | PL212428B1 (da) |
PT (1) | PT1542668E (da) |
RS (1) | RS51903B (da) |
RU (1) | RU2342931C2 (da) |
SI (1) | SI1542668T1 (da) |
TW (1) | TWI307626B (da) |
UA (1) | UA79984C2 (da) |
WO (1) | WO2004017897A2 (da) |
ZA (1) | ZA200501064B (da) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170705A1 (en) * | 2001-03-08 | 2004-09-02 | Dusan Miljkovic | Compositions and methods for non-insulin glucose uptake |
TWI307626B (en) * | 2002-08-20 | 2009-03-21 | Bristol Myers Squibb Co | Aripiprazole complex formulation and method |
DE602004017342D1 (de) | 2003-10-23 | 2008-12-04 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
PL1613598T3 (pl) * | 2003-12-16 | 2012-03-30 | Teva Pharma | Sposób wytwarzania krystalicznych form aripiprazolu |
US7714129B2 (en) | 2003-12-16 | 2010-05-11 | Teva Pharmaceutical Industries Ltd. | Methods of preparing anhydrous aripiprazole form II |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
WO2006113310A2 (en) * | 2005-04-13 | 2006-10-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives |
BRPI0613540A2 (pt) * | 2005-06-03 | 2011-01-18 | Elan Pharma Int Ltd | formulações de imatinib mesilato nanoparticuladas |
CA2611917A1 (en) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | Injection |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
CN101322709B (zh) * | 2007-06-12 | 2011-03-02 | 成都康弘药业集团股份有限公司 | 一种含有阿立哌唑的药物组合物及其制备方法 |
NZ582415A (en) | 2007-07-31 | 2012-05-25 | Otsuka Pharma Co Ltd | Methods for producing aripiprazole suspension and freeze-dried formulation |
WO2009048947A1 (en) * | 2007-10-09 | 2009-04-16 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors |
WO2009117401A2 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharama International Limited | Compositions for site-specific delivery of imatinib and methods of use |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
DK2445502T4 (da) * | 2009-06-25 | 2022-11-28 | Alkermes Pharma Ireland Ltd | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser |
WO2011023796A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox for treating addiction |
KR101125210B1 (ko) * | 2009-09-11 | 2012-03-19 | 주식회사 대웅제약 | 아리피프라졸-벤토나이트-aea 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법 |
US20110140304A1 (en) * | 2009-12-10 | 2011-06-16 | Molecular Imprints, Inc. | Imprint lithography template |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
RU2757859C2 (ru) | 2011-03-18 | 2021-10-21 | Алкермес Фарма Айэленд Лимитед | Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана |
US8969337B2 (en) | 2011-12-15 | 2015-03-03 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β-環糊精之藥物製劑 |
PT2814849T (pt) | 2012-02-15 | 2020-03-04 | Cydex Pharmaceuticals Inc | Processo de fabrico para derivados de ciclodextrina |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US10004807B2 (en) | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
GR1008186B (el) | 2013-04-22 | 2014-05-08 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
US20150086408A1 (en) * | 2013-09-26 | 2015-03-26 | General Electric Company | Method of manufacturing a component and thermal management process |
EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
GR1008442B (el) | 2014-01-16 | 2015-03-05 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης |
EP3119399A4 (en) | 2014-03-20 | 2017-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN105078910B (zh) * | 2015-09-22 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种含有依匹哌唑的冻干口服制剂及其制备方法 |
KR20180082457A (ko) | 2015-10-16 | 2018-07-18 | 마리누스 파마슈티컬스 인코포레이티드 | 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들 |
CN105616344A (zh) * | 2016-01-06 | 2016-06-01 | 万全万特制药江苏有限公司 | 阿立哌唑注射液及其制备方法 |
MX2019001323A (es) * | 2016-08-02 | 2019-07-04 | Univ Virginia Commonwealth | Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. |
JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. | てんかん性障害の処置のための方法および組成物 |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
TW201828938A (zh) | 2016-11-18 | 2018-08-16 | 德商艾庫里斯抗感染治療有限公司 | 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物,其製備方法及作為抗微生物醫藥組合物之用途 |
US11033506B2 (en) | 2017-11-21 | 2021-06-15 | Sekisui Chemical Co., Ltd. | External skin preparation comprising a core-shell structure |
WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2893175B2 (ja) * | 1988-10-31 | 1999-05-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
IT1269578B (it) | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
JPH10194996A (ja) | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
TWI307626B (en) * | 2002-08-20 | 2009-03-21 | Bristol Myers Squibb Co | Aripiprazole complex formulation and method |
CA2498276A1 (en) | 2002-10-25 | 2004-05-06 | Pfizer Products Inc. | Depot formulations of arylheterocyclic active agents in the form of a suspension |
-
2003
- 2003-08-14 TW TW092122407A patent/TWI307626B/zh not_active IP Right Cessation
- 2003-08-14 SI SI200331586T patent/SI1542668T1/sl unknown
- 2003-08-14 AU AU2003269965A patent/AU2003269965B2/en not_active Ceased
- 2003-08-14 DK DK03751859T patent/DK1542668T3/da active
- 2003-08-14 BR BR0313602-7A patent/BR0313602A/pt not_active Application Discontinuation
- 2003-08-14 CA CA2495864A patent/CA2495864C/en not_active Expired - Fee Related
- 2003-08-14 RU RU2005107471/15A patent/RU2342931C2/ru not_active IP Right Cessation
- 2003-08-14 NZ NZ537995A patent/NZ537995A/en not_active IP Right Cessation
- 2003-08-14 KR KR1020057002789A patent/KR101043866B1/ko active IP Right Grant
- 2003-08-14 PL PL374798A patent/PL212428B1/pl unknown
- 2003-08-14 EP EP03751859A patent/EP1542668B1/en not_active Expired - Lifetime
- 2003-08-14 JP JP2004531017A patent/JP4729306B2/ja not_active Expired - Fee Related
- 2003-08-14 MX MXPA05001865A patent/MXPA05001865A/es active IP Right Grant
- 2003-08-14 ES ES03751859T patent/ES2322953T3/es not_active Expired - Lifetime
- 2003-08-14 WO PCT/US2003/025573 patent/WO2004017897A2/en active Application Filing
- 2003-08-14 PT PT03751859T patent/PT1542668E/pt unknown
- 2003-08-14 UA UAA200502492A patent/UA79984C2/uk unknown
- 2003-08-14 US US10/642,366 patent/US7115587B2/en active Active
- 2003-08-14 RS YU20050118A patent/RS51903B/sr unknown
- 2003-08-14 GE GEAP8703A patent/GEP20063996B/en unknown
- 2003-08-14 DE DE60327225T patent/DE60327225D1/de not_active Expired - Lifetime
- 2003-08-14 CN CNB038195534A patent/CN100335047C/zh not_active Expired - Fee Related
- 2003-08-14 AT AT03751859T patent/ATE428423T1/de active
- 2003-08-15 MY MYPI20033103A patent/MY140793A/en unknown
- 2003-08-19 AR AR20030102990A patent/AR040887A1/es not_active Application Discontinuation
- 2003-08-20 PE PE2003000843A patent/PE20040895A1/es not_active Application Discontinuation
-
2005
- 2005-02-01 IL IL166623A patent/IL166623A/en active IP Right Grant
- 2005-02-04 ZA ZA200501064A patent/ZA200501064B/xx unknown
- 2005-02-08 NO NO20050661A patent/NO333458B1/no not_active IP Right Cessation
- 2005-02-16 HR HRP20050149AA patent/HRP20050149B1/hr not_active IP Right Cessation
- 2005-02-18 IS IS7701A patent/IS2878B/is unknown
-
2006
- 2006-06-14 US US11/452,782 patent/US7550445B2/en not_active Expired - Fee Related
-
2009
- 2009-04-02 US US12/417,067 patent/US20090186903A1/en not_active Abandoned
- 2009-07-07 CY CY20091100712T patent/CY1110331T1/el unknown
-
2011
- 2011-03-11 US US13/046,124 patent/US20110160224A1/en not_active Abandoned
- 2011-11-03 US US13/288,077 patent/US20120053145A1/en not_active Abandoned
-
2012
- 2012-10-22 US US13/656,785 patent/US20130045981A1/en not_active Abandoned
-
2013
- 2013-04-29 US US13/872,517 patent/US8999952B2/en not_active Expired - Fee Related
-
2015
- 2015-03-03 US US14/636,283 patent/US20150328335A1/en not_active Abandoned
- 2015-09-28 AR ARP150103114A patent/AR102101A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1542668T3 (da) | Formulering af aripiprazolkompleks og fremgangsmåde | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK1419776T3 (da) | Aripiprazol-lægemiddelsubstans med lav hygroskopi og fremgangsmåde til fremstilling af denne | |
NO2014027I1 (no) | Aripiprazol (preparat - krav 1 og 2 i patentet) | |
NO20051493L (no) | Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme | |
DK1539224T3 (da) | Antimikrobielt præparat og fremgangsmåde til anvendelse | |
DK1944322T3 (da) | Behandling af TNFalfa-relaterede sygdomme | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
NO20053874L (no) | Formulering og metoder for behandling av thrombocytemi | |
DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
DE60319810D1 (de) | Anschwemmfiltermedien und herstellungs- und verwendungsverfahren | |
IS8153A (is) | Ónæmisbælandi efnasambönd og efnablöndur | |
NO20041975L (no) | Bicyklisk oksopyridin og oksopyrimidinderivater | |
IS7699A (is) | Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma | |
IS7725A (is) | Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra | |
DK1641832T3 (da) | Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf | |
NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
DE60330269D1 (de) | Piperazinyl- und diazapanylbenzamide und-benzothioamide | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
NO20033506D0 (no) | Parasittdrepende preparater og fremgangsmåter for anvendelse | |
DE602004026773D1 (de) | Verfahrensherstellung von ethern | |
IS6979A (is) | 5-hluta heteróhringir, framleiðsla og notkun þeirra sem lyfja | |
ITMI20030178A1 (it) | Apparecchiatura e procedimento di fissaggio/ritenuta | |
ITTO20021118A1 (it) | Dispositivo mos e procedimento di fabbricazione di | |
ITTO20021119A1 (it) | Dispositivo mos e procedimento di fabbricazione di |